Skip to content


    DEA Class;  Rx

    Common Brand Names; Tudorza Pressair

    •  Anticholinergics, Respiratory

    Inhaled long-acting muscarinic antagonist (LAMA); given twice daily
    Used in adults for the maintenance treatment of COPD, including chronic bronchitis and/or emphysema
    Not indicated for the treatment of acute bronchospasm or asthma

    For the maintenance treatment of chronic obstructive pulmonary disease (COPD) (e.g., chronic bronchitis and emphysema).

    Hypersensitivity to drug or formulation components or severe hypersensitivity to milk proteins


    • Headache (6.6%)
    • Nasopharyngitis (5.5%)
    • Cough (3%)
    • Diarrhea (2.7%)
    • Sinusitis (1.7%)
    • Rhinitis (1.6%)
    • Toothache (1.1%)
    • Fall (1.1%)
    • Vomiting (1.1%)

    Postmarketing reports

    • Anaphylaxis
    • Angioedema (including swelling of lips and tongue or throat)
    • Urticaria
    • Rash
    • Bronchospasm
    • Itching
    • Nausea
    • Dysphonia
    • Blurred vision
    • Urinary retention
    • Tachycardia
    • Stomatitis

    Not for acute episodes of bronchospasm (ie, not for rescue therapy)

    May cause paradoxical bronchospasm; if this occurs, discontinue and consider other treatments

    Worsening of narrow-angle glaucoma may occur; use with caution in patients with narrow-angle glaucoma; prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (eg,eye pain or discomfort, blurred vision, visual halos, or colored images in association with red eyesfrom conjunctival congestion and corneal edema; instruct patients to consult a physician immediately if it occurs

    There are no adequate and well-controlled studies of aclidinium in pregnant women to assess drug-associated risks

    There are no available data on the breastfed child or on milk production or presence in human milk


    800 mcg (2 actuations)/day via oral inhalation.


    800 mcg (2 actuations)/day via oral inhalation.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.

    Aclidinium Bromide

    Metered-dose inhaler (dry powder)

    • 400mcg/actuation